文献速递呼吸危重症与机械通气呼吸道感染

肺移植治疗COVID-19相关ARDS的临床意义:全国性研究

Clinical relevance of lung transplantation for COVID-19 ARDS: a nationwide study.
PubMed 文献 · Eur Respir J · 2022-09-07

该研究基于奥地利全国住院患者登记数据,分析2020年1月1日至2021年5月30日期间COVID-19相关ARDS患者转诊至肺移植中心的情况。39 485例住院患者中,106例因重症COVID-19 ARDS被转诊,19例(18%)接受肺移植,移植后30天死亡率为0%,中位随访134(47-450)天时19例中14例存活。结论认为应早期将ECMO患者转诊至肺移植中心以筛选合适候选者。

要点

  • 重症COVID-19 ARDS患者中仅少数适合肺移植,需经移植中心筛选
  • ECMO支持患者应早期转诊至肺移植中心评估
  • 肺移植后30天死亡率为0%,中期结局良好

核心结论

  • 肺移植为部分不可逆肺损伤的重症COVID-19 ARDS患者提供良好中期结局,应纳入其治疗流程。
  • 早期将ECMO患者转诊至肺移植中心对筛选适合移植的患者至关重要。

研究设计与样本

  • 回顾性分析奥地利全国确诊SARS-CoV-2感染住院患者登记数据,入院时间为2020年1月1日至2021年5月30日。
  • 分析转诊至奥地利两家肺移植中心的患者,分为接受与拒绝肺移植两组,并对接受肺移植者与因其他指征移植者进行结局比较。

主要发现

  • 研究期间奥地利共39 485例COVID-19患者住院,其中2323例需机械通气,183例接受ECMO支持。
  • 106例重症COVID-19 ARDS患者被转诊至肺移植中心,19例(18%)接受肺移植。
  • COVID-19 ARDS移植受者移植后30天死亡率为0%。
  • 中位随访134(47-450)天时,19例中14例存活。

临床怎么用

  • 对依赖ECMO的重症COVID-19 ARDS患者应早期转诊至肺移植中心评估。
  • 肺移植可作为不可逆肺损伤患者的治疗选择之一,纳入post-COVID-19 ARDS治疗流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although the number of lung transplantations (LTx) performed worldwide for coronavirus disease 2019 (COVID-19)-induced acute respiratory distress syndrome (ARDS) is still low, there is general agreement that this treatment can save a subgroup of the most severely ill patients with irreversible lung damage. However, the true proportion of patients eligible for LTx, the overall outcome and the impact of LTx on the pandemic are unknown. METHODS: A retrospective analysis was performed using a nationwide registry of hospitalised patients with confirmed severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection admitted between 1 January 2020 and 30 May 2021 in Austria. Patients referred to one of the two Austrian LTx centres were analysed, and grouped into patients accepted and rejected for LTx. Detailed outcome analysis was performed for all patients who received a LTx for post-COVID-19 ARDS and compared with patients who underwent LTx for other indications. RESULTS: Between 1 January 2020 and 30 May 2021, 39 485 patients were hospitalised for COVID-19 in Austria. 2323 required mechanical ventilation and 183 received extracorporeal membrane oxygenation (ECMO) support. 106 patients with severe COVID-19 ARDS were referred for LTx. Of these, 19 (18%) underwent LTx. 30-day mortality after LTx was 0% for COVID-19 ARDS transplant recipients. At a median follow-up of 134 (47-450) days, 14 out of 19 patients were alive. CONCLUSIONS: Early referral of ECMO patients to a LTx centre is pivotal in order to select patients eligible for LTx. Transplantation offers excellent midterm outcomes and should be incorporated in the treatment algorithm of post-COVID-19 ARDS.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Lang C, Ritschl V, Augustin F, et al. Clinical relevance of lung transplantation for COVID-19 ARDS: a nationwide study. Eur Respir J. 2022. PMID: 35301249. doi:10.1183/13993003.02404-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。